Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS30066602HIVENSG00000106546.14protein_codingAHRNoNo196P35869
TVIS30066603HIVENSG00000106546.14protein_codingAHRNoNo196P35869
TVIS30066604HIVENSG00000106546.14protein_codingAHRNoNo196P35869
TVIS30066605HIVENSG00000106546.14protein_codingAHRNoNo196P35869
TVIS30066606HIVENSG00000106546.14protein_codingAHRNoNo196P35869
TVIS30066607HIVENSG00000106546.14protein_codingAHRNoNo196P35869
TVIS30066608HIVENSG00000106546.14protein_codingAHRNoNo196P35869
TVIS30066609HIVENSG00000106546.14protein_codingAHRNoNo196P35869
TVIS30066610HIVENSG00000106546.14protein_codingAHRNoNo196P35869
TVIS20041820HPVENSG00000106546.14protein_codingAHRNoNo196P35869
TCGA Plot Options
Drug Information
GeneAHR
DrugBank IDDB12379
Drug NameIndirubin
Target IDBE0003721
UniProt IDP35869
Regulation Typeagonist
PubMed IDs15056799; 25329374
CitationsAdachi J, Mori Y, Matsui S, Matsuda T: Comparison of gene expression patterns between 2,3,7,8-tetrachlorodibenzo-p-dioxin and a natural arylhydrocarbon receptor ligand, indirubin. Toxicol Sci. 2004 Jul;80(1):161-9. Epub 2004 Mar 31.@@Perkins A, Phillips JL, Kerkvliet NI, Tanguay RL, Perdew GH, Kolluri SK, Bisson WH: A Structural Switch between Agonist and Antagonist Bound Conformations for a Ligand-Optimized Model of the Human Aryl Hydrocarbon Receptor Ligand Binding Domain. Biology (Basel). 2014 Oct 17;3(4):645-69. doi: 10.3390/biology3040645.
GroupsInvestigational
Direct ClassificationIndolines
SMILESO=C1NC2=C(C=CC=C2)C1=C1/NC2=C(C=CC=C2)C1=O
Pathways
PharmGKB
ChEMBL